Atea Pharmaceuticals secures credit facility of up to $200 million from Hercules Capital

By Public Technologies
  • Atea Pharmaceuticals secured a credit facility of up to $200 million from Hercules Capital, receiving $65 million at closing.
  • Additional funding includes up to $35 million tied to a clinical milestone and $70 million tied to regulatory, financing and commercial milestones.
  • A further $30 million may be available at the borrower's request, subject to lenders' sole discretion.
  • The facility matures in 60 months; its 48-month interest-only period can extend to 60 months upon achieving a specified commercial milestone.
  • Existing cash, cash equivalents and investments, together with initial proceeds, are expected to fund planned operations into mid-2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872971) on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.